CPMD · XBRL financial data

Cannapharmarx financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CPMD's year ends in late December)

In thousands of dollars	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q1 FY24†Mar 31, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q1 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0*	0	0	0	26	312	482*	232	657	139*	627	276
Cost of goods and services sold	—	0	—	0	463	668	year only	853	1,097	660*	1,037	415
Gross profit	—	0	—	0	(437)	(356)	—	(621)	(440)	(521)*	(409)	(138)
Selling, general and administrative	—	—	—	337	—	51	(137)*	—	—	—	—	—
General and administrative	1,716*	250	271	337	209	51	(137)*	76	145	230*	36	83
Total operating expenses	3,204*	720	893	667	353	142	(170)*	220	496	372*	273	240
Operating income (loss)	(3,204)*	(720)	(893)	(667)	(790)	(498)	(1,521)*	(841)	(936)	(894)*	(682)	(379)
Interest expense	847*	459	355	355	576	632	322*	658	506	179*	476	349*
Other income (expense)	—	—	—	—	—	—	year only	—	—	year only	300	—
Income tax expense (benefit)	0*	0	0	—	—	—	year only	0	—	year only	—	0
Net income (loss)	(3,639)*	(1,413)	(1,880)	(564)	(11,716)	188	(3,741)	(1,413)	(1,478)	(7,550)*	(382)	(1,909)
Earnings per share, basic USD per share	—	0.00	(0.01)	0.00	(0.03)	—	—	0.00	—	—	—	0.00
Earnings per share, diluted USD per share	—	0.00	(0.01)	0.00	(0.03)	0.00	—	0.00	0.00	—	0.00	0.00
Weighted average shares, basic thousands of shares	252,563*	292,890	299,656	295,096	350,520	662,501	—	662,501	662,501	—	—	682,482
Weighted average shares, diluted thousands of shares	252,563*	292,890	299,656	295,096	350,520	662,501	—	662,501	—	—	669,790	682,482

† Share count changed about 2x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (CPMD's year ends in late December)

In thousands of dollars	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q1 FY24†Mar 31, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q1 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	2	0	0	0	12	7	2	17	1	2	1	1
Accounts receivable	—	—	—	—	14	—	2	—	—	164	7	7
Inventory	—	—	—	—	950	1,220	996	1,044	864	1,115	903	1,306
Total current assets	100	104	42	54	1,047	1,497	1,019	1,198	1,471	1,311	930	1,333
Property and equipment, net	108	103	173	167	150	154	137	129	123	127	176	200
Right-of-use asset	—	—	—	—	5,650	5,512	5,161	5,627	5,505	5,580	5,475	5,358
Total assets	5,414	5,271	5,323	5,156	11,366	11,681	10,836	11,473	11,617	7,018	6,581	6,892
Accounts payable	6,883	7,178	7,771	7,772	8,290	8,953	4,784	5,458	5,613	5,470	—	10,477
Accrued liabilities	—	—	—	—	—	—	4,303	4,365	4,387	4,399	—	—
Total current liabilities	17,165	17,838	19,650	20,229	29,252	22,503	25,752	28,954	28,481	31,590	31,486	32,570
Lease liability, non-current	—	—	—	—	—	—	4,893	—	—	5,034	4,931	4,818
Total liabilities	22,759	23,482	25,467	25,786	34,895	28,266	30,645	34,047	34,134	37,172	36,851	37,723
Accumulated deficit	(94,695)	(96,108)	(97,987)	(98,552)	(102,994)	(97,443)	(101,184)	(103,288)	(104,766)	(112,316)	(112,698)	(114,607)
Total stockholders' equity	(17,344)	(18,210)	(20,144)	(20,630)	(23,529)	(16,585)	(19,810)	(22,574)	(22,517)	(30,154)	(30,270)	(30,831)
Total liabilities and equity	5,414	5,271	5,323	5,156	11,366	11,681	10,836	11,473	11,617	7,018	6,581	6,892
Common shares outstanding (cover page) thousands of shares	298,987	300,863	300,863	337,961	662,501	662,501	662,501	662,501	662,501	662,501	678,501	708,690

† Share count changed about 2x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (CPMD's year ends in late December)

In thousands of dollars	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q1 FY24†Mar 31, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q1 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,639)*	(1,413)	(1,880)	(564)	(11,716)	188	(3,741)	(1,413)	(1,478)	(7,550)*	(382)	(1,909)
Stock-based compensation	45*	45	45	45	0	0	—	—	—	—	—	—
Depreciation and amortization	—	6	—	—	23	0	—	0	0	—	—	—
Net cash from operating activities	(425)*	(612)	(482)*	124*	(549)	(541)*	(180)*	(446)*	(803)*	1,061*	(244)	(127)*
Purchases of property and equipment	—	1	—	—	0	—	0*	—	—	year only	—	—
Net cash from investing activities	(9)*	(1)	(74)*	(4)*	0	—	0*	—	—	year only	—	—
Proceeds from issuing common stock	0*	0	0*	0*	—	—	—	—	—	—	—	—
Proceeds from long-term debt	218*	—	—	—	—	—	150*	0*	—	—	—	—
Net cash from financing activities	95*	493	461*	93*	560	539*	175*	462*	787*	(1,855)*	242	182*
Net change in cash	(204)*	(2)	0*	—	11	(2)*	(5)*	16*	(16)*	1*	(1)	(0)*

† Share count changed about 2x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cannapharmarx	0.6	276	(127)*	708.7M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Propanc Biopharma	832	not reported	(1,602)*	6.3M	0.5 quarters	Q4 FY26 10-KJun 30, 2026
MetaVia	12,634	not reported	(3,762)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Scorpius Holdings	582	not reported	(2,917)*	61.1M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Nomad Power Solutions	12,670	not reported	(1,612)*	16.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.